Pharmacyclics Inc.
995 E Arques Avenue
Sunnyvale,
CA 94085-4521
United States - Map
Phone: 408-774-0330
Fax: 408-774-0340
Web Site: http://www.pharmacyclics.com
| Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. The companys products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer. The company was founded in 1991 and is headquartered in Sunnyvale, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Robert W. Duggan , 64
Chairman and Chief Exec. Officer |
$
0 |
$
0 | Dr. Glenn C. Rice Ph.D., 53
Pres, Chief Operating Officer |
$
18.00K | N/A | Dr. Richard A. Miller M.D., 58
Co-Founder and Consultant |
$
121.00K |
$
0 | Mr. Leiv Lea , 55
Consultant |
$
97.00K |
$
0 | Dr. Joseph J. Buggy Ph.D., 42
VP of Research |
$
192.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.27% Nasdaq 
Profile
